NDAQ:AZN - Post Discussion
Post by
whytestocks on Feb 19, 2024 2:30am
Datopotamab Deruxtecan Biologics License Application Accepte
Just In: $AZN Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerApplication based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (L...
AZN - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Be the first to comment on this post